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Members of the Nogo66 receptor family (NgR) are closely associated with nerve growth inhibition and
plasticity in the CNS. All three members, NgR1, NgR2 and NgR3, are GPI anchored and highly glycosylated
proteins. The binding and signaling properties of NgR1 are well described, but largely unknown for NgR2.
At present the only known ligands are myelin associated glycoprotein (MAG) and amyloid beta precursor
protein (APP). Despite the requirement of co-receptors for signaling no other binding partner has been
uncovered. To learn more about the interactome of NgR2 we performed pull down experiments and were
able to identify F-box protein that recognizes sugar chain 1 (Fbs1) as binding partner. We conﬁrmed this
ﬁnding with co-immunoprecipitations and in vitro binding assays and showed that the binding is med-
iated by the substrate recognition domain of Fbs1. As a substrate recognition protein of the SCF complex,
Fbs1 binding leads to polyubiquitination and ﬁnally degradation of its substrates.
This is the ﬁrst time a member of the Nogo receptor family has been connected with an intracellular
degradation pathway, which has not only implications for its production, but also for amyloid deposition
in Alzheimer’s disease.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
As a result of a various number of inhibitory molecules and their
cognate receptors the regeneration capacity of the CNS is very lim-
ited [1]. One of the ﬁrst described nerve growth inhibitors was
Nogo-A [2–4], which signals through binding to Nogo receptor 1
(NgR1) and its complex members Lingo and p75NTR/Troy [5–9].
The very same receptor complex is also used by myelin associated
glycoprotein (MAG) and oligodendrocyte myelin glycoprotein
(OMgp) [6,10]. This signaling results in the activation of RhoA fol-
lowed by growth cone collapse [11,12]. Subsequently, other CNS ex-
pressed members of the Nogo receptor family were identiﬁed and
denoted NgR2 and NgR3 [13–15]. Despite the high degree of homol-
ogy neither NgR2 nor NgR3 bind Nogo-A. The only common ligands
are MAG for NgR1 and NgR2 [14,16,17] and amyloid beta precursor
protein (APP) for all three familymembers [18]. In fact, unlike NgR1,
for NgR2 and NgR3 no co-receptor has been identiﬁed yet.
All members of the Nogo receptor family share a very similar
domain structure. They consist of a leucine rich repeat domain
and a C-terminal stalk region, which shows the highest degree of
variation. Furthermore, all three proteins are GPI anchored and gly-
cosylated proteins [16]. The binding of MAG by NgR2 was shown to
be sialic acid dependent [14].Y-NC-ND license. 
F. Kern).In our study we describe the binding of F-box protein that rec-
ognizes sugar chain 1 (Fbs1), also called Fbx2, Fbxo2 and OCP1, to
NgR2. It is expressed mainly in the brain [19] and in the organ of
Corti [20]. Fbs1 is a substrate recognizing member of the SCF com-
plex, which is a multi-protein E3 ubiquitin ligase containing Skp1,
Cullin1 and a variable F-box protein. It recognizes high-mannose
type polysaccharides and either functions as a chaperon [21] or
leads to polyubiquitination and ﬁnally to degradation [22].
Furthermore, it was shown that Fbs1 also interacts with another
protein known for glycoprotein homeostasis, CHIP, a co-chaperon
with ubiquitin ligase properties. This interaction increased the
turnover rate of Fbs1 bound glycoproteins [23]. In addition overex-
pression of Fbs1 in Alzheimer disease model mice reduced BACE1
levels and led to reduced synaptic deﬁcits [24]. This is particular
interesting because the NgRs are also known to bind APP
[18,25,26] and NgR2 knock out reduced plaque formation [18].
Here we provide the ﬁrst evidence that NgR2 is a substrate of
Fbs1, which ﬁnally could also regulate its level.2. Materials and methods
2.1. Plasmid construction
Mouse NgR2 mRNA sequence (91-1167) was subcloned in the
plasmid pIgj-V5-NgR [27] using the BamHI – PmeI sites and the
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CCT ATG CTC TGC ACC TGC TAC TCC TCC 30 and re 50 CAG GTT TAA
ACT CAT TTT TCG AAC TGC GGG TGG CTC CAC AGC GCT CCC GGG
CAC GCT TGG AAA TCG GAG TCG CTC 30. C-terminal a synthesized
double strep-tag was inserted using the AfeI site and the oligos 50
TAG CGG CGG CGG ATG GAG CCA CCC GCA GTT CGA AAA AGG 30
and 50 CCT TTT TCG AAC TGC GGG TGG CTC CAT CCG CCG CCG
CTA 30. Sequencing revealed a double insertion of the oligo result-
ing in a triple strep-tag, which showed higher afﬁnity compared to
single tag.
The ﬂag tagged NgR2 construct was cloned into pAPtag5 vector
using the restriction enzymes HindIII and XbaI (Fermentas) and the
Primers fw 50 CGA AGC TTA CGA TTA CAA GGA TGA CGA CGA TAA
GTC CGT GAC CCC CAG CTG TCC 30 and re 50 TAT TCT AGA TCA GAG
GTG ATG GAG CGC CAG 30. The forward primer encodes the
ﬂag tag. The derived construct uses the signal peptide from the
pAPtag5 followed by the ﬂag tag and the NgR2 coding sequence
starting with amino acid 30. The C-terminus including the GPI
anchor sequence is not changed.
Fbs1 full length was ampliﬁed from mouse brain cDNA using
the primers fw 50 ATT GCT AGC GCG ATG GAT GGA GAT GGT G
30and re 50 ATT CTC GAG GGG TTC CAC CCA CAC GCT AC 3 and
cloned into pAPtag5 vector (Genehunter) using NheI and XhoI
sites. The construct thus has a C-terminal myc/his tag.
Plasmids containing the wild type sugar binding domain of Fbs1
and mutant F177A were kindly provided by Yoshida (Tokyo Metro-
politan Institute of Medical Science) [28].
All constructs were sequenced (LGC) to verify the successful
cloning. Schemes of all used constructs can be seen in Fig. 1(A).
2.2. Pull down assay
CHO K1 cells adapted to grow in suspension were transiently
transfected with NgR2 strep using Amaxa™Nucleofector™ (Lonza).Fig. 1. (A) Wild type NgR2 consists of a signal peptide (SP), a leucine-rich repeat domai
region. The cloned NgR2-strep constructs uses the signal peptide and V5 tag of the vect
(STrEP). The NgR2-Flag has a N-terminal ﬂag tag (F) and the wild type C-terminus. Fbs1
We added a C-terminal myc tag for the Fbs1-myc construct. The constructs SBD and F177A
SDS–PAGE (5%–15%) and silverstained. Recombinant bait protein NgR2-strep is marked w
of the single band from B resulted in the identiﬁcation of the peptides marked with und4 days after transfection conditioned medium was harvested and
dialysed extensively against PBS. It was then applied to a mini col-
umn containing 150 ll strep-TactinSepharose (IBA, 2-1201-010).
After extensive washing 10 mg total protein of whole mouse brain
lysate was applied. Adult C57Bl6 mice were decapitated and whole
brainwas lysed in buffer A (50 mMHepes pH 7.6, 150 mMNaCl, 10%
glycerol, 1% triton x-100, 1 mM PMSF, 5 lg/ml leupeptin and 10 lg/
ml aprotinin) and cleared by centrifugation. Protein concentration
was measured using Protein assay (Bio-Rad, 500-0006). Column
was washed three times with buffer A and eluted using elution buf-
fer (IBA, 2-1019-025). Sample was either separated by SDS–PAGE
followed by MALDI-TOF analysis of single silverstained bands, run
on SDS–PAGE followed by coomassie staining and analysis by
LC/MS/MS, or TCA precipitated and analyzed by LC/MS/MS.
Silverstaining was performed as described [29]. Experiments were
controlled by use of empty beads for pull downs. In addition also
the puriﬁed NgR2 was analyzed, to ensure only binding partners
from brain lysate are considered.2.3. MALDI TOF
Relevantproteinbandwas excised fromgel, destained, and in-gel
digested with modiﬁed porcine trypsin, sequence grade (Promega)
as described in [30]. Micro-ZipTipC18 (Millipore) were utilized for
digest desalting, and peptides were eluted with the acetonitrile
solution containing the CHCAmatrix (Fluka) directly onto the target.
Mass spectra were acquired using a MALDI-TOF/TOF Ultraﬂex
instrument (Bruker Daltonics). Peptide mass ﬁngerprintings (PMF)
were interpreted with the MASCOT by scanning the SwissProt data-
base. A peptide mass tolerance was set to 0.1 Da and one missed
cleavage was allowed; a complete carbamidomethylation of cyste-
ines and partial oxidation of methionines were considered as
modiﬁcations.n (LRRs) ﬂanked by a N-terminal ﬂank (NF) and a C-terminal ﬂank (CF) and a Stalk
or backbone, avoids the GPI anchor sequence and has a C-terminal triple-strep-tag
consists of a PEST, F-Box and the substrate recognition sugar binding domain (SBD).
have a N-terminal HIS tag (H). (B) Pull down experiment was separated on gradient
ith black arrow and band identiﬁed to be Fbs1 marked with arrow head. (C) Analysis
erlined bold letters. The sequence coverage is 36%.
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Protein digests were analyzed using nanoLC-ESI-MS (LTQ Orbi-
trap XL; ThermoScientiﬁc) equipped with a nanospray interface
and coupled to an UltiMate 3000 system (Dionex). The nano-HPLC
separation was done as described by Faserl et al. [31]. Protein iden-
tiﬁcation was performed via Sequest, Proteome Discoverer
(Version 1.1, ThermoScientiﬁc) and a mouse database. The criteria
for positive identiﬁcation of peptides were Xcorr > 2.3 for doubly
charge ions, and Xcorr > 2.8 for triply charge ions and Xcorr > 3.3
for fourfold and higher charged ions.
TCA precipitated and acetone washed protein pellets were
reduced with TCEP, alkylated with jodoacetamide and digested
with trypsin. Peptides were analyzed by nanoLC-MSMS with a
1200 HPLC (Agilent) connected to a LTQ Orbitrap Velos (Thermo
Scientiﬁc). The proteins were identiﬁed with Mascot searching
Swiss-Prot 2010_09 [32].
2.5. Co-Immunoprecipitations
NgR2-ﬂag and Fbs1-myc/his were co-transfected in CHO K1
cells using Lipofectamine 2000 (Invitrogen, 11668019). Two days
after transfection cells were lysed in buffer A and used for immu-
noprecipitation. 1 mg of lysate (5 lg/ll total protein), 2 lg of ﬂag
antibody (Sigma–Aldrich, F1804), 2 lg of myc (Sigma–Aldrich,
M4439) antibody and as control 2 lg of anti strep antibody (IBA,
2-1507-001) was used per reaction. Samples were incubated 1 h
with antibodies followed by 1 h with protein A/G agarose (Pierce,
20421). After washing with buffer A samples were boiled in 1 lae-
mmli buffer for 10 min and analyzed by Western blotting using 3%
skim milk in TBST for blocking, anti-ﬂag antibody 1:1000 (Sigma–
Aldrich, F1804) and polyclonal anti-myc antibody 1:1000 (Santa
Cruz, SC-789) as primary antibodies. As secondary antibodies
HRP labeled goat anti mouse IgG 1:20000 (Thermo Scientiﬁc-
Pierce, 31430) and goat anti rabbit IgG 1:20000 (Thermo Scien-
tiﬁc-Pierce, 31460) were used.
2.6. In vitro binding assays
NgR2 strep was puriﬁed as described in previous paragraph. The
sugar binding domain and the F177A mutant, both His tagged,
were produced in E.coli BL21 and puriﬁed using TALON Metal
Afﬁnity Resin (Clontech, 635501) according to manufacturer. 1 lg
of puriﬁed sugar binding domains were incubated with 500 ng
NgR2 bound to 15 ll bed volume of strep-tactin Sepharose. After
washing with strep-tag washing buffer (IBA, 2-1003-100) the sam-
ple was eluted using biotin containing elution buffer (IBA, 2-1019-
025) and analysed by SDS–PAGE and silverstaining [29] and by
western blotting using HRP labeled anti-HIS antibody (Novagen,
71840-3) and anti V5 antibody (Invitorgen, R0960-25).3. Results
NgR2 is known to be a receptor for MAG, but also inﬂuences the
plaque formation in Alzheimer’s disease by interacting with APP.
To increase our knowledge about this receptor we performed pull
down assays. We used suspension CHO K1 culture to produce trun-
cated NgR2 protein containing a C-terminal triple-strep-tag
(Fig. 1(A)). The mammalian system was chosen to ensure proper
glycosylation. The protein was secreted into the protein free
medium (CD CHO, Invitrogen) and subsequently puriﬁed using
the strep-tactin system. The combination of secretion in protein
free media and the use of triple-strep-tag allowed a one step puri-
ﬁcation. The recombinant bait protein was bound by strep-tactin
Sepharose and used directly for pull down assays using 10 mg totalprotein of adult mouse brain lysate. Two separate negative controls
were included to reveal for non speciﬁc protein binding. Firstly, the
same amount of empty beads were used for pull down to ensure
only speciﬁc binding partners were analyzed. In addition NgR2
beads without brain lysate was used to ensure only binding part-
ners coming from the brain lysate were considered.
We separated the samples using SDS–PAGE and analyzed single
bands migrating at 42 kDa using a MALDI-TOF mass spectrometry,
which led to the identiﬁcation of Fbs1 as a unique band in the pull
down lane (Fig. 1(B)). In total, all peptides that were identiﬁed cor-
respond to 36% of Fbs1 (Fig. 1(C)).
To analyze the pull down experiments in more detail we used
additional approaches. The samples were either run on SDS–PAGE
and extracted from gel, or TCA precipitated followed by LC/MS/MS
using either a LTQ Orbitrap XL or a LTQ Orbitrap Velos. With the
gain in sensitivity we found in addition to Fbs1 its binding partner
Skp1 in the pull down samples. However other members of the SCF
complex were not identiﬁed, which is in accordance with the ﬁnd-
ing that Fbs1 forms a complex mainly with Skp1 and not necessar-
ily the full SCF complex including Cul1 [33]. The sequence coverage
was 75% for Fbs1 and 76% for Skp1. The unique peptides identiﬁed
for both proteins can be seen in Table 1. In all experiments not a
single spectra of both Fbs1 and Skp1 was found in the controls.
In addition to this novel interaction we were also able to pull down
MAG, reported previously to interact with NgR2 [14], supporting
the speciﬁcity of the pull-down assay. The LC/MS/MS data for
MAG are shown in the Supplementary data (Table S1). Interest-
ingly no other sugar binding F-box protein was identiﬁed. In par-
ticular, Fbs2 (Fbxo6), which is highly expressed in brain and is
known to bind partly the same substrates [34], was not seen in
any pull down samples analyzed.
To further validate the authenticity of the proteins identiﬁed by
mass spectrometry, we performed co-immunoprecipitation exper-
iments. Myc tagged Fbs1 was co-expressed with NgR2-ﬂag in CHO
cells. When precipitating Fbs1 using an anti-myc antibody, we ob-
served a strong signal for ﬂag tagged NgR2. Similarly for precipita-
tion of NgR2 using an anti-ﬂag antibody a clear signal for myc
tagged Fbs1 was seen. An unrelated anti-strep antibody failed to
precipitate both proteins (Fig. 2(A)). This conﬁrmed our initial ﬁnd-
ing of the pull down experiments. Due to the lack of a speciﬁc NgR2
antibody, we were not able to also perform co-immunoprecipita-
tion experiments in endogenous material.
Fbs1 is known to bind mannose rich polysaccharides without
any speciﬁcity concerning amino acid sequence. NgR2 is strongly
glycosylated [14,35] and therefore it is likely that the Fbs1 binding
depends on its sugar binding domain. To address this hypothesis
we performed in vitro binding assays using recombinant NgR2 pro-
duced in CHO cells and the sugar binding domain (SBD) of Fbs1 and
a mutant (F177A) expressed in E.coli. The mutation F177A is sufﬁ-
cient to completely abolish the binding of Fbs1 to substrates [28].
NgR2 was bound to strep-tactin Sepharose and incubated either
with puriﬁed recombinant SBD or F177A. Subsequently samples
were washed and separated by SDS–PAGE, followed either by silver
staining (Fig. 2(B)) or Western blotting (Fig. 2(C)). As expected,
only the wt SBD was able to bind, demonstrating that NgR2 bind-
ing is mediated via the substrate binding domain of Fbs1 and not
via its PEST and F-box domains. Therefore NgR2 is considered to
be a novel substrate of Fbs1.4. Discussion
Although NgR2 is known to be a receptor of MAG its physiolog-
ical role is still unclear. Recently the ability of NgR2 to alter the
plaque formation in Alzheimer’s disease model mice [18] renewed
the interest in NgR2.
Table 1
Peptides of Fbs1 (A) and Skp1 (B) identiﬁed by LC/MS/MS. The sequence coverage is 75% for Fbs1 and 76% for
Skp1 as indicated by underlined and bold amino acids.
Peptide mass Sequence
2771.33 EAEEEEEAEAVEYLAELPEPLLLR
1668.89 VLAELPATELVQAcR
1666.95 WKELVDGAPLWLLK
1353.77 ELVDGAPLWLLK
3282.48 cQQEGLVPEGSADEERDHWQQFYFLSK
2500.99 NPcGEEDLEGWSDVEHGGDGWR
1498.72 DHWQQFYFLSK
2206.03 VEELPGDNGVEFTQDDSVKK
1352.58 YFASSFEWcR
3056.61 KAQVIDLQAEGYWEELLDTTQPAIVVK
1323.67 TDAGSLYELTVR
4394.07 LLSENEDVLAEFATGQVAVPEDGSWMEISHTFIDYGPGVR
1452.65 FEHGGQDSVYWK
1 MDGDGDPESV SHPEEASPEE QPEEAGAEAS AEEEQLREAE EEEEAEAVEY
51 LAELPEPLLL RVLAELPATE LVQACRLVCL RWKELVDGAP LWLLKCQQEG
101 LVPEGSADEE RDHWQQFYFL SKRRRNLLRN PCGEEDLEGW SDVEHGGDGW
151 RVEELPGDNG VEFTQDDSVK KYFASSFEWC RKAQVIDLQA EGYWEELLDT
201 TQPAIVVKDW YSGRTDAGSL YELTVRLLSE NEDVLAEFAT GQVAVPEDGS
251 WMEISHTFID YGPGVRFVRF EHGGQDSVYW KGWFGARVTN SSVWVEP
B
Peptide mass Sequence
2317.21 PTIKLqSSDGEIFEVDVEIAK
1877.93 LQSSDGEIFEVDVEIAK
2535.31 LQSSDGEIFEVDVEIAKQSVTIK
3124.5 TMLEDLGMDDEGDDDPVPLPNVNAAILKK
1760.87 RTDDIPVWDQEFLK
2135.15 VDQGTLFELILAANYLDIK
904.47 GLLDVTcK
2068.97 TFNIKNDFTEEEEAQVR
1465.64 NDFTEEEEAQVR
1250.54 KENQWcEEK
1 MPTIKLQSSD GEIFEVDVEI AKQSVTIKTM LEDLGMDDEG DDDPVPLPNV
51 NAAILKKVIQ WCTHHKDDPP PPEDDENKEK RTDDIPVWDQ EFLKVDQGTL
101 FELILAANYL DIKGLLDVTC KTVANMIKGK TPEEIRKTFN IKNDFTEEEE
151 AQVRKENQWC EEK
Fig. 2. (A) Fbs1-myc co-precipitated NgR2-ﬂag and vice versa. An unrelated antibody against the strep-tag did not precipitate Fbs1 nor NgR2. (B) In vitro binding assay was
analyzed by silver staining. While the wild type sugar binding domain (SBD) (arrow head) bound the bait protein (arrow), the F177A mutant lost this binding completely. (C)
Analyzing the in vitro binding assay with western blotting, using an anti V5 antibody to detect the NgR2-strep (arrow) and a HRP labeled anti HIS antibody to detect the sugar
binding domains (arrow head), showed binding of the wild type construct and only weak background signal for F177A mutant.
980 F. Kern et al. / Biochemical and Biophysical Research Communications 417 (2012) 977–981Our results show binding of NgR2 via the sugar binding domain
of Fbs1. Interestingly, only Fbs1 and not Fbs2 was identiﬁed in our
pull down assay. Both proteins are known to bind partly the same
substrates and are both expressed in the brain [19,22,34].Fbs1 is a cytoplasmic protein and can bind its substrates only in
this compartment. The substrate needs to be retro-translocated be-
fore being recognized. This transport is known to take place from
the ER and endosomes to the cytoplasm [36,37]. After binding the
F. Kern et al. / Biochemical and Biophysical Research Communications 417 (2012) 977–981 981substrates are polyubiquitinated and degraded via the proteasome.
Interestingly several substrates of Fbs1 showdecreased levels when
Fbs1 is overexpressed [23,24,37,38]. One explanation would be that
the degradation process is limited by this F-box protein.
Our ﬁnding has relevance in Alzheimer’s disease. Recently a
study showed that overexpression of Fbs1 in Alzheimer’s disease
models resulted in reduced BACE1 andmost importantly in a rescue
of synaptic deﬁcits [24]. Here we show that NgR2 is also bound by
the substrate recognition site of Fbs1. As there is no amino acid spec-
iﬁcity of this special F-box protein, we propose that NgR2 levels
might also be reduced by Fbs1 overexpression. Reduction of NgR2
was shownto reduceamyloiddepositionand therefore is considered
to be beneﬁcial [18]. The reduction of BACE1 by Fbs1 overexpression
might well be accompanied by reduced NgR2 levels, which both
leads to reduced plaque formation and rescue of synaptic deﬁcits.
To consider Fbs1 as therapeutic target is however risky and
needs further investigation. In our opinion the substrate recogni-
tion is not ideal, because there is no amino acid sequence speciﬁc-
ity. This means that there are probably hundreds of N-glycosylated
proteins, that might be degraded via Fbs1 binding. This makes a
reasonable calculation of side effects challenging. That is why it
is important to identify as many substrates of Fbs1 as possible.
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